ASKG-712 is under clinical development by AffaMed Therapeutics US and currently in Phase I for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase I drugs for Wet (Neovascular / Exudative) Macular Degeneration have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ASKG-712’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ASKG-712 overview

ASKG-712 is under development for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema and retinal vein occlusion (RVO-ME). It is administered through intravitreal route. The therapeutic candidate acts by targeting vascular endothelial growth factor A (VEGFA) and angiopoietin 2 (ANG2).

AffaMed Therapeutics US overview

AffaMed Therapeutics US (AffaMed Therapeutics) is a biopharmaceutical company that develops and commercializes drugs for the treatment of ophthalmology, neurology and psychiatric indications. The company is investigating AM007, a corticosteroid intracanalicular insert for post-surgical pain and inflammation, AM008 program against glaucoma, AM002 and AM003 drugs to treat wet age-related macular degeneration and diabetic macular edema. AffaMed Therapeutics is also evaluating AM004, a proposed biosimilar targeting paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD); AM005 against social anxiety disorder; and AM006 for Parkinson’s disease. It works in partnership with Ocular Therapeutix Inc, VistaGen Therapeutics Inc and other biopharmaceutical companies. It operates in China and the US. AffaMed Therapeutics is headquartered in New York, the US.

For a complete picture of ASKG-712’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.